INDIANAPOLIS--(BUSINESS WIRE)--Oct 29, 2024--
DecisionRx, Inc., a value-based healthcare company reducing the cost of care by helping individuals eliminate medication failure, today announced that seasoned healthcare executive Michael Tilton has been appointed as Chief Growth Officer. In this role, Tilton will lead the company’s activities to expand commercialization of the DecisionRx Medication Therapy Optimization (MTO) platform.
“DecisionRx has been implemented by payers and accountable care organizations (ACOs) across the US, and Michael has joined the team to accelerate adoption of our MTO platform by even more organizations— ultimately benefitting more physicians and patients,” said DecisionRx co-founder and president Travis Morgan. “DecisionRx clinical pharmacists use pharmacogenomics and evidence-based clinical insights to help prescribers replace trial-and-error prescribing with truly personalized medication therapy for their patients. We can save over $3,600 per year in avoidable healthcare costs among Medicare patients. Michael’s deep industry experience and professional network will be instrumental as we continue to expand our footprint with ACOs, Medicare Plans, and Employers who share our vision for clinically optimized medication therapy, personalized to each individual.”
Tilton most recently served as Senior Vice President of Specialty and Retiree Solutions at Humana, where he managed a portfolio of businesses representing over $12.7 billion in annual revenue. At Humana he was responsible for managing the Ancillary Group, Individual and Medicare Supplemental Benefits, Wellness, Medicare Supplement, and Group Medicare businesses, with active involvement in enterprise-level projects to reduce costs and improve operating efficiency.
Prior to Humana, Tilton held senior leadership positions at Blue Cross Blue Shield of Arizona, UnitedHealth Group, Cigna, GlaxoSmithKline, and US Healthcare. His experiences span PBM contracting, payer access, health outcomes, provider contracting, underwriting, finance, and product/go-to-market strategies.
“The DecisionRx MTO platform empowers prescribers to improve patient health while reducing the human and financial burdens of medications that don’t work,” said Tilton. “In my experience, the DecisionRx model represents a unique opportunity to shift the healthcare cost curve in a way that aligns with the needs of patients, providers, and payers alike. I believe this value-based care model will quickly become the gold standard in the industry.”
About DecisionRx
DecisionRx is a technology-enabled healthcare services company, improving patient outcomes and reducing healthcare costs by helping physicians optimize prescribing decisions for their patients. DecisionRx clinical pharmacists work on patients’ behalf to mitigate medication failure by making personalized medication recommendations to prescribers, informed by the latest clinical and data-science, and delivered in a value-based care model. Medication failure accounts for at least 16% of total healthcare spending, and medication therapy optimization has been shown to reduce total annualized cost of care by $3,600 for Medicare patients and $1,200 for patients under age 65.
View source version on businesswire.com:https://www.businesswire.com/news/home/20241029800536/en/
CONTACT: Media
Alexis Feinberg
ICR Westwicke on behalf of DecisionRx
646-277-1252
Alexis.Feinberg@westwicke.com
KEYWORD: INDIANA UNITED STATES NORTH AMERICA